Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer
In cancer, various MMPs play a role in progression and metastasis and their overexpression generally indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14...
Gespeichert in:
| Veröffentlicht in: | Diagnostic pathology 2016-04, Vol.11 (34), p.34-34, Article 34 |
|---|---|
| Hauptverfasser: | , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 34 |
|---|---|
| container_issue | 34 |
| container_start_page | 34 |
| container_title | Diagnostic pathology |
| container_volume | 11 |
| creator | Vos, M Caroline van der Wurff, Anneke A M Bulten, Johan Kruitwagen, Roy Feijen, Harrie van Kuppevelt, Toin H Hendriks, Thijs Massuger, Leon F A G |
| description | In cancer, various MMPs play a role in progression and metastasis and their overexpression generally indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14 and MMP-2 in ovarian cancer. This study was designed to determine the prognostic value of MMP-14 and MMP-2 expression in ovarian cancer with data on long-term follow-up.
Tumor samples of 94 consecutive ovarian cancer patients from one regional laboratory were evaluated. Clinical and survival data were collected and related to known prognostic factors, as well as to the expression of MMP-14 and MMP-2 as determined by semi-quantitative immunohistochemistry.
Epithelial MMP-14 expression correlated with stromal MMP-14 expression (rho = .47, p |
| doi_str_mv | 10.1186/s13000-016-0485-3 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4818939</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A448361554</galeid><sourcerecordid>A448361554</sourcerecordid><originalsourceid>FETCH-LOGICAL-c494t-278f3bdf7613d03b4e1276e750b4049d077caf4c71373b2b08d7f4a7af56a8543</originalsourceid><addsrcrecordid>eNptUk1v1TAQtBCIlsIP4IIsceGSdh07sXNBqioKSK-ih_ZsOf54uErsYCdP8O_r9JXSVsiSvVrPzO7ag9B7AseEiPYkEwoAFZC2Aiaair5Ah4SztiJN1758FB-gNznfALCmqeE1Oqg5UNECP0TXGz_62Rrsg7GTLVuY8ZTiNsQ8e413algsjg5fXFxWhGEVzF1YY_t7SjZnH0Ph4rhTyauAtQraprfolVNDtu_uzyN0ff7l6uxbtfnx9fvZ6abSrGNzVXPhaG8cbwk1QHtmSc1byxvoGbDOAOdaOaY5oZz2dQ_CcMcUV65plWgYPUKf97rT0o_W6NJ8UoOckh9V-iOj8vLpTfA_5TbuJBNEdLQrAp_uBVL8tdg8y9FnbYdBBRuXLAnngkPHxVrr4zPoTVxSKOMVVFdGEIzQf6itGqz0wcVSV6-i8pQxQVvS3PV9_B9UWcaOXsdgnS_5JwSyJ-gUc07WPcxIQK5ekHsvyOIFuXpBrq18ePw4D4y_n09vAXbxrKk</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1797618413</pqid></control><display><type>article</type><title>Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>SpringerLink Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>PubMed Central Open Access</source><source>Springer Nature OA Free Journals</source><creator>Vos, M Caroline ; van der Wurff, Anneke A M ; Bulten, Johan ; Kruitwagen, Roy ; Feijen, Harrie ; van Kuppevelt, Toin H ; Hendriks, Thijs ; Massuger, Leon F A G</creator><creatorcontrib>Vos, M Caroline ; van der Wurff, Anneke A M ; Bulten, Johan ; Kruitwagen, Roy ; Feijen, Harrie ; van Kuppevelt, Toin H ; Hendriks, Thijs ; Massuger, Leon F A G</creatorcontrib><description>In cancer, various MMPs play a role in progression and metastasis and their overexpression generally indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14 and MMP-2 in ovarian cancer. This study was designed to determine the prognostic value of MMP-14 and MMP-2 expression in ovarian cancer with data on long-term follow-up.
Tumor samples of 94 consecutive ovarian cancer patients from one regional laboratory were evaluated. Clinical and survival data were collected and related to known prognostic factors, as well as to the expression of MMP-14 and MMP-2 as determined by semi-quantitative immunohistochemistry.
Epithelial MMP-14 expression correlated with stromal MMP-14 expression (rho = .47, p < .01) and epithelial MMP-2 expression was found to correlate with both MMP-14 epithelial and stromal expression (rho = -.28, p < .01 respectively rho = -.21, p < .05). In univariable analysis of 64 advanced-staged tumours, no MMP parameter was significant for progression-free or overall survival. In multivariable analysis for PFS, stromal MMP-14 expression and epithelial MMP-2 expression remained in the model. For overall survival, no MMP parameter showed significance.
We confirmed the correlation between epithelial and stromal MMP-14 expression and between epithelial MMP-2 and both epithelial and stromal MMP-14 expression. In this study with long-term follow-up, the independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer is limited to a role in PFS for stromal MMP-14 expression and epithelial MMP-2 expression.</description><identifier>ISSN: 1746-1596</identifier><identifier>EISSN: 1746-1596</identifier><identifier>DOI: 10.1186/s13000-016-0485-3</identifier><identifier>PMID: 27038607</identifier><language>eng</language><publisher>England: BioMed Central Ltd</publisher><subject>Adult ; Aged ; Aged, 80 and over ; Analysis ; Biomarkers, Tumor - analysis ; Care and treatment ; Complications and side effects ; Disease-Free Survival ; Epithelial Cells - enzymology ; Female ; Humans ; Immunohistochemistry ; Kaplan-Meier Estimate ; Matrix Metalloproteinase 14 - analysis ; Matrix Metalloproteinase 2 - analysis ; Metastasis ; Middle Aged ; Multivariate Analysis ; Neoplasm Staging ; Netherlands ; Ovarian cancer ; Ovarian Neoplasms - enzymology ; Ovarian Neoplasms - mortality ; Ovarian Neoplasms - pathology ; Ovarian Neoplasms - therapy ; Proportional Hazards Models ; Retrospective Studies ; Risk Factors ; Stromal Cells - enzymology ; Time Factors ; Treatment Outcome</subject><ispartof>Diagnostic pathology, 2016-04, Vol.11 (34), p.34-34, Article 34</ispartof><rights>COPYRIGHT 2016 BioMed Central Ltd.</rights><rights>Copyright BioMed Central 2016</rights><rights>Vos et al. 2016</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c494t-278f3bdf7613d03b4e1276e750b4049d077caf4c71373b2b08d7f4a7af56a8543</citedby><cites>FETCH-LOGICAL-c494t-278f3bdf7613d03b4e1276e750b4049d077caf4c71373b2b08d7f4a7af56a8543</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818939/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC4818939/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,27901,27902,53766,53768</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/27038607$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Vos, M Caroline</creatorcontrib><creatorcontrib>van der Wurff, Anneke A M</creatorcontrib><creatorcontrib>Bulten, Johan</creatorcontrib><creatorcontrib>Kruitwagen, Roy</creatorcontrib><creatorcontrib>Feijen, Harrie</creatorcontrib><creatorcontrib>van Kuppevelt, Toin H</creatorcontrib><creatorcontrib>Hendriks, Thijs</creatorcontrib><creatorcontrib>Massuger, Leon F A G</creatorcontrib><title>Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer</title><title>Diagnostic pathology</title><addtitle>Diagn Pathol</addtitle><description>In cancer, various MMPs play a role in progression and metastasis and their overexpression generally indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14 and MMP-2 in ovarian cancer. This study was designed to determine the prognostic value of MMP-14 and MMP-2 expression in ovarian cancer with data on long-term follow-up.
Tumor samples of 94 consecutive ovarian cancer patients from one regional laboratory were evaluated. Clinical and survival data were collected and related to known prognostic factors, as well as to the expression of MMP-14 and MMP-2 as determined by semi-quantitative immunohistochemistry.
Epithelial MMP-14 expression correlated with stromal MMP-14 expression (rho = .47, p < .01) and epithelial MMP-2 expression was found to correlate with both MMP-14 epithelial and stromal expression (rho = -.28, p < .01 respectively rho = -.21, p < .05). In univariable analysis of 64 advanced-staged tumours, no MMP parameter was significant for progression-free or overall survival. In multivariable analysis for PFS, stromal MMP-14 expression and epithelial MMP-2 expression remained in the model. For overall survival, no MMP parameter showed significance.
We confirmed the correlation between epithelial and stromal MMP-14 expression and between epithelial MMP-2 and both epithelial and stromal MMP-14 expression. In this study with long-term follow-up, the independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer is limited to a role in PFS for stromal MMP-14 expression and epithelial MMP-2 expression.</description><subject>Adult</subject><subject>Aged</subject><subject>Aged, 80 and over</subject><subject>Analysis</subject><subject>Biomarkers, Tumor - analysis</subject><subject>Care and treatment</subject><subject>Complications and side effects</subject><subject>Disease-Free Survival</subject><subject>Epithelial Cells - enzymology</subject><subject>Female</subject><subject>Humans</subject><subject>Immunohistochemistry</subject><subject>Kaplan-Meier Estimate</subject><subject>Matrix Metalloproteinase 14 - analysis</subject><subject>Matrix Metalloproteinase 2 - analysis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Multivariate Analysis</subject><subject>Neoplasm Staging</subject><subject>Netherlands</subject><subject>Ovarian cancer</subject><subject>Ovarian Neoplasms - enzymology</subject><subject>Ovarian Neoplasms - mortality</subject><subject>Ovarian Neoplasms - pathology</subject><subject>Ovarian Neoplasms - therapy</subject><subject>Proportional Hazards Models</subject><subject>Retrospective Studies</subject><subject>Risk Factors</subject><subject>Stromal Cells - enzymology</subject><subject>Time Factors</subject><subject>Treatment Outcome</subject><issn>1746-1596</issn><issn>1746-1596</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2016</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><recordid>eNptUk1v1TAQtBCIlsIP4IIsceGSdh07sXNBqioKSK-ih_ZsOf54uErsYCdP8O_r9JXSVsiSvVrPzO7ag9B7AseEiPYkEwoAFZC2Aiaair5Ah4SztiJN1758FB-gNznfALCmqeE1Oqg5UNECP0TXGz_62Rrsg7GTLVuY8ZTiNsQ8e413algsjg5fXFxWhGEVzF1YY_t7SjZnH0Ph4rhTyauAtQraprfolVNDtu_uzyN0ff7l6uxbtfnx9fvZ6abSrGNzVXPhaG8cbwk1QHtmSc1byxvoGbDOAOdaOaY5oZz2dQ_CcMcUV65plWgYPUKf97rT0o_W6NJ8UoOckh9V-iOj8vLpTfA_5TbuJBNEdLQrAp_uBVL8tdg8y9FnbYdBBRuXLAnngkPHxVrr4zPoTVxSKOMVVFdGEIzQf6itGqz0wcVSV6-i8pQxQVvS3PV9_B9UWcaOXsdgnS_5JwSyJ-gUc07WPcxIQK5ekHsvyOIFuXpBrq18ePw4D4y_n09vAXbxrKk</recordid><startdate>20160402</startdate><enddate>20160402</enddate><creator>Vos, M Caroline</creator><creator>van der Wurff, Anneke A M</creator><creator>Bulten, Johan</creator><creator>Kruitwagen, Roy</creator><creator>Feijen, Harrie</creator><creator>van Kuppevelt, Toin H</creator><creator>Hendriks, Thijs</creator><creator>Massuger, Leon F A G</creator><general>BioMed Central Ltd</general><general>BioMed Central</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FD</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FR3</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>M7Z</scope><scope>P64</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope></search><sort><creationdate>20160402</creationdate><title>Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer</title><author>Vos, M Caroline ; van der Wurff, Anneke A M ; Bulten, Johan ; Kruitwagen, Roy ; Feijen, Harrie ; van Kuppevelt, Toin H ; Hendriks, Thijs ; Massuger, Leon F A G</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c494t-278f3bdf7613d03b4e1276e750b4049d077caf4c71373b2b08d7f4a7af56a8543</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2016</creationdate><topic>Adult</topic><topic>Aged</topic><topic>Aged, 80 and over</topic><topic>Analysis</topic><topic>Biomarkers, Tumor - analysis</topic><topic>Care and treatment</topic><topic>Complications and side effects</topic><topic>Disease-Free Survival</topic><topic>Epithelial Cells - enzymology</topic><topic>Female</topic><topic>Humans</topic><topic>Immunohistochemistry</topic><topic>Kaplan-Meier Estimate</topic><topic>Matrix Metalloproteinase 14 - analysis</topic><topic>Matrix Metalloproteinase 2 - analysis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Multivariate Analysis</topic><topic>Neoplasm Staging</topic><topic>Netherlands</topic><topic>Ovarian cancer</topic><topic>Ovarian Neoplasms - enzymology</topic><topic>Ovarian Neoplasms - mortality</topic><topic>Ovarian Neoplasms - pathology</topic><topic>Ovarian Neoplasms - therapy</topic><topic>Proportional Hazards Models</topic><topic>Retrospective Studies</topic><topic>Risk Factors</topic><topic>Stromal Cells - enzymology</topic><topic>Time Factors</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Vos, M Caroline</creatorcontrib><creatorcontrib>van der Wurff, Anneke A M</creatorcontrib><creatorcontrib>Bulten, Johan</creatorcontrib><creatorcontrib>Kruitwagen, Roy</creatorcontrib><creatorcontrib>Feijen, Harrie</creatorcontrib><creatorcontrib>van Kuppevelt, Toin H</creatorcontrib><creatorcontrib>Hendriks, Thijs</creatorcontrib><creatorcontrib>Massuger, Leon F A G</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Technology Research Database</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Engineering Research Database</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Biochemistry Abstracts 1</collection><collection>Biotechnology and BioEngineering Abstracts</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Diagnostic pathology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Vos, M Caroline</au><au>van der Wurff, Anneke A M</au><au>Bulten, Johan</au><au>Kruitwagen, Roy</au><au>Feijen, Harrie</au><au>van Kuppevelt, Toin H</au><au>Hendriks, Thijs</au><au>Massuger, Leon F A G</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer</atitle><jtitle>Diagnostic pathology</jtitle><addtitle>Diagn Pathol</addtitle><date>2016-04-02</date><risdate>2016</risdate><volume>11</volume><issue>34</issue><spage>34</spage><epage>34</epage><pages>34-34</pages><artnum>34</artnum><issn>1746-1596</issn><eissn>1746-1596</eissn><abstract>In cancer, various MMPs play a role in progression and metastasis and their overexpression generally indicates a poor prognosis. MMP-14 is the main activator of MMP-2 and both molecules play a role in normal ovarian follicular development. Earlier reports indicated a prognostic value for both MMP-14 and MMP-2 in ovarian cancer. This study was designed to determine the prognostic value of MMP-14 and MMP-2 expression in ovarian cancer with data on long-term follow-up.
Tumor samples of 94 consecutive ovarian cancer patients from one regional laboratory were evaluated. Clinical and survival data were collected and related to known prognostic factors, as well as to the expression of MMP-14 and MMP-2 as determined by semi-quantitative immunohistochemistry.
Epithelial MMP-14 expression correlated with stromal MMP-14 expression (rho = .47, p < .01) and epithelial MMP-2 expression was found to correlate with both MMP-14 epithelial and stromal expression (rho = -.28, p < .01 respectively rho = -.21, p < .05). In univariable analysis of 64 advanced-staged tumours, no MMP parameter was significant for progression-free or overall survival. In multivariable analysis for PFS, stromal MMP-14 expression and epithelial MMP-2 expression remained in the model. For overall survival, no MMP parameter showed significance.
We confirmed the correlation between epithelial and stromal MMP-14 expression and between epithelial MMP-2 and both epithelial and stromal MMP-14 expression. In this study with long-term follow-up, the independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer is limited to a role in PFS for stromal MMP-14 expression and epithelial MMP-2 expression.</abstract><cop>England</cop><pub>BioMed Central Ltd</pub><pmid>27038607</pmid><doi>10.1186/s13000-016-0485-3</doi><tpages>1</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1746-1596 |
| ispartof | Diagnostic pathology, 2016-04, Vol.11 (34), p.34-34, Article 34 |
| issn | 1746-1596 1746-1596 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_4818939 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; SpringerLink Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; PubMed Central Open Access; Springer Nature OA Free Journals |
| subjects | Adult Aged Aged, 80 and over Analysis Biomarkers, Tumor - analysis Care and treatment Complications and side effects Disease-Free Survival Epithelial Cells - enzymology Female Humans Immunohistochemistry Kaplan-Meier Estimate Matrix Metalloproteinase 14 - analysis Matrix Metalloproteinase 2 - analysis Metastasis Middle Aged Multivariate Analysis Neoplasm Staging Netherlands Ovarian cancer Ovarian Neoplasms - enzymology Ovarian Neoplasms - mortality Ovarian Neoplasms - pathology Ovarian Neoplasms - therapy Proportional Hazards Models Retrospective Studies Risk Factors Stromal Cells - enzymology Time Factors Treatment Outcome |
| title | Limited independent prognostic value of MMP-14 and MMP-2 expression in ovarian cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T09%3A23%3A39IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Limited%20independent%20prognostic%20value%20of%20MMP-14%20and%20MMP-2%20expression%20in%20ovarian%20cancer&rft.jtitle=Diagnostic%20pathology&rft.au=Vos,%20M%20Caroline&rft.date=2016-04-02&rft.volume=11&rft.issue=34&rft.spage=34&rft.epage=34&rft.pages=34-34&rft.artnum=34&rft.issn=1746-1596&rft.eissn=1746-1596&rft_id=info:doi/10.1186/s13000-016-0485-3&rft_dat=%3Cgale_pubme%3EA448361554%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1797618413&rft_id=info:pmid/27038607&rft_galeid=A448361554&rfr_iscdi=true |